Galileo: Plotting nutraceutical stars

Because of the redundancy inherent in biological systems, physiological states are extremely complex. Galileo Laboratories Inc. has based its technology platform on the assumption that altering complex physiological states requires that multiple molecular targets be addressed.

"The juggernaut in drug discovery is functional biology," said Chairman and CEO Guy Miller. For example, he noted that in sepsis, a cell exhibits a function or behavior in which multiple molecular entities are involved. Galileo tries to look at high probability targets and produce combinations of lead compounds against them. The combinations are the basis of the company's nutraceutical products and also serve as a foundation for a drug discovery program...